Patients newly diagnosed with multiple myeloma must decide whether to pursue a bone marrow transplant, if they are eligible. But if they defer this option, the anti-CD38 antibody daratumumab (Darzalex Faspro, Johnson & Johnson), given subcutaneously with a standard backbone […]
Talquetamab, the bispecific GPRC5D-directed CD3 T-cell engager, offered durable responses when used in different combinations, according to data from a pair of trials involving patients with multiple myeloma who had received 4 to 5 prior lines of therapy. Updated phase
Talquetamab Combo Updates Show Durable Responses in Heavily Pretreated Patients Read More »
It’s hard to find a cancer conference—or any health care meeting—that doesn’t offer something on the wonders of artificial intelligence (AI), and the International Myeloma Society 21st Annual Meeting & Exposition, taking place in Rio de Janiero, Brazil September 25-28,
Fine-tuning AI Tools to Make Meaningful Predictions in Cancer Read More »
Despite the advances in treating multiple myeloma, some patients relapse early even when given the latest triplet and quadruplet combination therapies and maintenance following a stem cell transplant. At the International Myeloma Society 21st Annual Meeting & Exposition Thursday, experts
Reaching Consensus on Defining, Treating High-Risk Myeloma Read More »
It’s been almost 50 years since “monoclonal gammopathy of undetermined significance,” or MGUS, was identified as a precursor to multiple myeloma. Yet the debate over when and how to treat patients who have not developed the organ damage associated with
Risk Factors, Who to Treat, How to Treat Read More »
More than 20 years after the first papers on the topic appeared, use of minimal residual disease (MRD) negativity is poised to become a common surrogate end point in accelerated approvals for therapies for multiple myeloma and perhaps for other
After ODAC, What’s Next for MRD Testing in Multiple Myeloma? Read More »
